Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma

2008126 citationsJournal Articlegreen Open Access

Authors

Domingo G. Pérez · Metro-Minnesota Community Oncology Research Consortium

Vera J. Suman · Mayo Clinic

Tom R. Fitch · Mayo Clinic in Arizona

Thomas Amatruda · Metro-Minnesota Community Oncology Research Consortium

Roscoe F. Morton · Iowa Oncology Research Association

Shamim Z. Jilani · Dayton Clinical Oncology Program

Costas L. Constantinou

Abstract

This combination of carboplatin, paclitaxel, and bevacizumab appears to be moderately well tolerated and clinically beneficial in patients with metastatic melanoma. Further study of this combination is warranted.

Topics & Keywords

Melanoma and MAPK Pathways HER2/EGFR in Cancer Research Cutaneous Melanoma Detection and Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 115, Issue 1, pp. 119-127

DOI: 10.1002/cncr.23987

Field-Weighted Citation Impact: 8.44